Health Technology Assessment in Action

Published by: Kowsar

Comparing the Quality of Life in Patients with Stroke Under the Treatment with and Without Recombinant Tissue Plasminogen Activator

Zahra Goudarzi 1 , Zhila Najafpour 2 and Nahid Hatam 3 , *
Authors Information
1 Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Health Care Management, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Health Service Administration, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
Article information
  • Health Technology Assessment in Action: April 30, 2018, 2 (1); e88716
  • Published Online: June 23, 2019
  • Article Type: Research Article
  • Received: January 5, 2019
  • Revised: May 29, 2019
  • Accepted: June 10, 2019
  • DOI: 10.5812/htaa.88716

To Cite: Goudarzi Z, Najafpour Z, Hatam N. Comparing the Quality of Life in Patients with Stroke Under the Treatment with and Without Recombinant Tissue Plasminogen Activator, Health Tech Asmnt Act. 2018 ; 2(1):e88716. doi: 10.5812/htaa.88716.

Copyright © 2019, Health Technology Assessment in Action. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Cerniauskaite M, Quintas R, Koutsogeorgou E, Meucci P, Sattin D, Leonardi M, et al. Quality-of-life and disability in patients with stroke. Am J Phys Med Rehabil. 2012;91(13 Suppl 1):S39-47. doi: 10.1097/PHM.0b013e31823d4df7. [PubMed: 22193309].
  • 2. Abubakar SA, Isezuo SA. Health related quality of life of stroke survivors: Experience of a stroke unit. Int J Biomed Sci. 2012;8(3):183-7. [PubMed: 23675271]. [PubMed Central: PMC3615283].
  • 3. Opara JA, Jaracz K. Quality of life of post-stroke patients and their caregivers. J Med Life. 2010;3(3):216-20. [PubMed: 20945810]. [PubMed Central: PMC3018998].
  • 4. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61(1):46-55. doi: 10.1016/j.annemergmed.2012.04.020. [PubMed: 22633340]. [PubMed Central: PMC3598015].
  • 5. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke. 2003;34(6):1437-42. doi: 10.1161/01.STR.0000072513.72262.7E. [PubMed: 12730560].
  • 6. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945-8. doi: 10.1161/STROKEAHA.109.192535. [PubMed: 19478221]. [PubMed Central: PMC2782817].
  • 7. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001;32(8):1832-40. doi: 10.1161/01.STR.32.8.1832. [PubMed: 11486113].
  • 8. Mahmoodi M, Safari A, Vossoughi M, Golbon-Haghighi F, Kamali-Sarvestani M, Ghaem H, et al. Stroke specific quality of life questionnaire: Test of reliability and validity of the Persian version. Iran J Neurol. 2015;14(2):94-100. [PubMed: 26056554]. [PubMed Central: PMC4449400].
  • 9. Tseng MC, Chang KC. Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: A comparative review. Acta Neurol Taiwan. 2004;13(3):149-55. [PubMed: 15508942].
  • 10. I. S. T. Collaborative Group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12(8):768-76. doi: 10.1016/S1474-4422(13)70130-3. [PubMed: 23791822]. [PubMed Central: PMC3854835].
  • 11. Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032-9. doi: 10.1161/STROKEAHA.114.005852. [PubMed: 25190439].
  • 12. Araujo DV, Teich V, Passos RB, Martins SC. Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke. Arq Bras Cardiol. 2010;95(1):12-20. doi: 10.1590/s0066-782x2010005000067. [PubMed: 20563521].
  • 13. Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. J Med Econ. 2018;21(3):282-7. doi: 10.1080/13696998.2017.1401545. [PubMed: 29105528].
  • 14. de Haan RJ, Limburg M, Van der Meulen JH, Jacobs HM, Aaronson NK. Quality of life after stroke. Impact of stroke type and lesion location. Stroke. 1995;26(3):402-8. doi: 10.1161/01.STR.26.3.402. [PubMed: 7886714].
  • 15. Kar N, John SP. Site of stroke : Correlation with cognitive deficits, symptoms of anxiety and depression, and quality of life. Indian J Psychiatry. 2003;45(4):218-20. [PubMed: 21206861]. [PubMed Central: PMC2952367].
  • 16. Khayatzadeh-Mahany M, Goharpei S, Rostami HR, Jahantabinezhad S. [Comparative study of quality of life in stroke patients in Ahwaz]. Zahedan J Res Med Sci. 2011;14(2):86-90. Persian.
  • 17. Fattahi A, Azad A, Montazeri A. [Quality of life among stroke patients in kermanshah city]. Novin Rehabil J. 2008;2(1):1-8. Persian.
  • 18. Durmaz T, Özdemİr Ö, Özdemİr BA, Keleş T, Bayram NA, Bozkurt E. Factors affecting quality of life in patients with coronary heart disease. Turkish J Med Sci. 2009;39(3):343-51.
  • 19. Jafari M, Dalvandi A. [Quality of life of stroke survivors and its related factors]. Iran J Nur. 2014;27(87):14-22. Persian.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments